Skip navigation

Leadership Seminar – Immunotherapies: Hype, Hope and Reality

10:00 - 18:30

Location:
The Cambridge Building, Babraham Research Campus, Cambridge CB22 3AT
Date:
10 October 2017
 
Supported by:

 

Recent years have seen major advances in our understanding of complex disease mechanisms and the molecular engineering tools that allowed the concept of immunotherapy to become a reality. A range of biotechs emerged with a variety of therapeutic approaches raising interest in the investor and pharma communities as potential providers of breakthrough therapies tacking the 21st Century healthcare challenges.

It is now starting to deliver for patients with a recent example of the approval of Keytruda, but success must be balanced with the many challenges left whether regarding understanding of toxicity effects, drug delivery, patient segmentation, manufacturing and market access.

This Leadership Seminar will provide an overview of where the Immunotherapy field is currently with presentations from a variety of companies on their approaches in immuno-oncology as still the dominant application but also other therapeutic areas. It will also discuss some of the challenges faced on the development pathway.

It should appeal to any academic or therapeutic company in the field of immunotherapies as well as anyone fascinated by this fast moving sector.

Programme

09.30 - Registration over Tea and Coffee

10.15 - Welcome

Scene Setting

10.25 - Overview of Industry Activity and Deals
Adrian Dawkes, PharmaVentures 

10.45 – Immuno-Oncology: Current and Future Advances  
Robert Wilkinson, MedImmune

11.15 – The Role of Antibody Isotype and Fc Receptor Interactions in Immunostimulatory Anti-Cancer Immunotherapy
Stephen Beers, University of Southampton

11.45 - The Immunobiology of Immunotherapy
Camilo Colaço, immBio

12.15 – Lunch

13.35 - Innovative Approach to New Therapeutics in Immune-Oncology

13.35 - Effective Treatment of Metastatic Melanoma Using a GMP - Manufactured T Cell Therapy
Neill Moray Mackenzie, Immetacyte

14.00 - The Use of Bispecific Antibodies to Modulate Anti-Tumour Immune Responses
Neil Brewis, F-star

14.25 - Elevated Tryptophan Catabolism in the Tumour Microenvironment
Andrew Mellor, Newcastle University 

14.50 - Using Oncolytic Viruses to Drive Tumour Immune Responses
Richard Brown, Psioxus 

15.15 – Break

15.45 – Tackling Challenges on the Development Pathway 

15.45 - Biomarker Validation
Alex Phipps, Roche

16.10 - Optimisation of Model Selection
Winfried Elis, Charles River

16.35 - Early Stage Developability Assessment for Biotherapeutics’.
Noel Smith, Lonza Biologics

17.00 - Closing Remarks and Drinks Reception

18.30 - Close 


Prices:
Gold Members: £75 +VAT 
Silver Members: £175 +VAT 
Non-Members: £275 +VAT
Academics: £75 + VAT – please contact aline@onenucleus.com for your discount code.
 



Title: Leadership Seminar – Immunotherapies: Hype, Hope and Reality
Start: 2017-10-10 10:00:00Z
End: 2017-10-10 18:30:00Z